Adiponectin levels in myeloma patients after curcumin supplementation: A randomized clinical pilot study
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Curcumin supplementation may increase adiponectin levels in multiple myeloma patients. This study suggests that adding curcumin to standard treatment could benefit patients by potentially improving this key biomarker.
Area Of Science
- Oncology
- Biochemistry
- Nutritional Science
Background
- Multiple myeloma is linked to low adiponectin, a condition associated with various diseases.
- Curcumin is known to inhibit adipogenesis and increase adiponectin.
- Few studies have explored curcumin's effect on adiponectin in myeloma patients.
Purpose Of The Study
- To evaluate the efficacy of curcumin supplements in increasing adiponectin levels among multiple myeloma patients.
- To investigate the impact of curcumin on serum adiponectin in the context of standard myeloma treatment.
Main Methods
- A randomized study comparing melphalan, prednisone, and curcumin (MPC) to melphalan and prednisone (MP) with placebo.
- Patients received either MPC (8g curcumin daily) or MP for four 28-day cycles.
- Serum adiponectin and other biomarkers were measured before and after treatment.
Main Results
- Serum adiponectin levels were higher in the MPC group compared to the MP group after four treatment cycles.
- The mean adiponectin level in the MPC group was 12227.1±5748.3, versus 11365.4±9175.5 in the MP group (P=0.78).
Conclusions
- Daily curcumin supplementation (8000 mg) alongside standard chemotherapy increases serum adiponectin levels in myeloma patients.
- Myeloma patients may experience benefits from incorporating curcumin supplements into their treatment regimen.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.